The Food and Drug Administration requested that Tetraphase Pharmaceuticals Inc. (Nasdaq: TTPH) conduct an additional phase 3 clinical trial to support its New Drug Application for IV eravacycline sending the stock price tumbling 72 cents to close at $3.47.
FDA asks Tetraphase Pharmaceutical to conduct additional trial
May 13, 2016 at 20:15 PM EDT
